Efficacy of Dexamethasone in Adhesive Small Bowel Obstruction
ANZ Journal of Surgery · 2026
DOI: 10.1111/ans.70706 ↗Kurz gefasst
Fachartikel in der Zeitschrift ANZ Journal of Surgery, 2026. Verfasst von Supun M Bakmiwewa und 7 weiteren Autor:innen. Beteiligte Einrichtung: Innovation, Surgical Teaching and Research (iSTAR) Unit, Liverpool Hospital, Sydney, Australia. Hauptthemen laut MEDLINE: Dexamethasone, Intestinal Obstruction, Intestine, Small, Postoperative Complications. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Small bowel obstruction (SBO) is a common long‐term complication following abdominal surgery and a frequent cause of inpatient admissions. The most common cause of SBO is adhesions, followed by hernias and malignancy. Non‐operative management strategies include bowel rest, nasogastric decompression, and Gastrografin administration, each with their own advantages and risks. Intravenous (IV) corticosteroids (Dexamethasone) have demonstrated benefit in malignant SBO but remain unexamined in adhesive SBO. The aim of this study is to evaluate the role of Dexamethasone in adhesive SBO.
Methods
A retrospective review of all patients admitted with adhesive SBO to a tertiary Colorectal Unit between 2020 and 2024 was performed. Demographics, patient results and interventional data were collected. All patients received nasogastric decompression, and IV Dexamethasone was used based on surgeon preference. For analysis, the cohort was divided into two: those who received Dexamethasone (Dex) and those who didn't (Control).
Results
A total of 105 patients were included with a mean age of 63.5 years and 54% male. There was no significant difference in baseline characteristics between the two groups. In the Dex group, 92% (46/50) resolved with non‐operative management, compared to 75% (41/55) in the Control group, which was statistically significant ( p = 0.018). There was no difference in Gastrografin use or the length of stay between the two groups.
Conclusion
IV Dexamethasone was safe and significantly reduced the need for surgical intervention in adhesive SBO. This is the first study which evaluates the use of IV Dexamethasone in non‐malignant SBO and a randomised clinical trial is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Innovation, Surgical Teaching and Research (iSTAR) Unit, Liverpool Hospital, Sydney, Australia.
- Department of Colorectal Surgery, Liverpool Hospital, Sydney, Australia.
- Faculty of Medicine, University of New South Wales, Sydney, Australia.
- School of Medicine, Western Sydney University, Sydney, Australia.
- Faculty of Medicine, University of Sydney, Sydney, Australia.
- Department of Surgery, Macquarie University Hospital, Sydney, Australia.
ORCID-Profile: Supun M Bakmiwewa, Mina Sarofim
Zitieren
APA
Bakmiwewa, S. M., Sarofim, M., Cheng, E., Yeh, D., MacKenzie, S., Gibson, K., Gilmore, A., & Zahid, A. (2026). Efficacy of Dexamethasone in Adhesive Small Bowel Obstruction. ANZ Journal of Surgery. https://doi.org/10.1111/ans.70706
Vancouver
Bakmiwewa SM, Sarofim M, Cheng E, Yeh D, MacKenzie S, Gibson K, et al. Efficacy of Dexamethasone in Adhesive Small Bowel Obstruction. ANZ Journal of Surgery. 2026. doi:10.1111/ans.70706
BibTeX
@article{Bakmiwewa2026,
author = {Bakmiwewa, Supun M and Sarofim, Mina and Cheng, Ernest and Yeh, Dean and MacKenzie, Scott and Gibson, Katherine and Gilmore, Andrew and Zahid, Assad},
title = {Efficacy of Dexamethasone in Adhesive Small Bowel Obstruction},
journal = {ANZ Journal of Surgery},
year = {2026},
doi = {10.1111/ans.70706}
}
EUVIMED